Display options
Cite
Jeger RV, Greenberg JD, Ramanathan K, et al. Lumiracoxib, a highly selective COX-2 inhibitor. Expert Rev Clin Immunol. 2005;1(1):37-45doi: 10.1586/1744666X.1.1.37.
Jeger, R. V., Greenberg, J. D., Ramanathan, K., & Farkouh, M. E. (2005). Lumiracoxib, a highly selective COX-2 inhibitor. Expert review of clinical immunology, 1(1), 37-45. https://doi.org/10.1586/1744666X.1.1.37
Jeger, Raban V, et al. "Lumiracoxib, a highly selective COX-2 inhibitor." Expert review of clinical immunology vol. 1,1 (2005): 37-45. doi: https://doi.org/10.1586/1744666X.1.1.37
Jeger RV, Greenberg JD, Ramanathan K, Farkouh ME. Lumiracoxib, a highly selective COX-2 inhibitor. Expert Rev Clin Immunol. 2005 May;1(1):37-45. doi: 10.1586/1744666X.1.1.37. PMID: 20477653.
Copy Download .nbib Format: NLM
Share it on

Expert Rev Clin Immunol. 2005 May;1(1):37-45. doi: 10.1586/1744666X.1.1.37.

Lumiracoxib, a highly selective COX-2 inhibitor.

Expert review of clinical immunology

Raban V Jeger, Jeffrey D Greenberg, Krishnan Ramanathan, Michael E Farkouh

Affiliations

  1. New York University School of Medicine, Cardiovascular Clinical Research Center, VA, NY 10010, USA. [email protected]

PMID: 20477653 DOI: 10.1586/1744666X.1.1.37

Abstract

Lumiracoxib Prexige, Novartis AG) is a highly selective inhibitor of cyclooxygenase-2 that has been approved in 22 countries including the UK for analgesic therapy in chronic and acute pain. For patients with osteoarthritis, the recommended initial dose is 100 or 200 mg once daily, in one or two divided doses. In patients with primary dysmenorrhea, or following dental or orthopedic surgery with moderate-to-severe acute pain, the recommended dose is 400 mg once daily. The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) tested the efficacy and gastrointestinal safety of the drug against two traditional nonselective nonsteroidal anti-inflammatory drugs, naproxen and ibuprofen. The results from this trial demonstrated that lumiracoxib reduces gastrointestinal ulcer complication rates by 66% overall and 79% among nonaspirin users in a population without gastroprotection. Lumiracoxib was not associated with a statistically significant difference in cardiovascular morbidity and mortality compared with nonselective nonsteroidal anti-inflammatory drugs. However, in view of the ongoing debate about the safety of cyclooxygenase-2 inhibitors, the use of this drug class should be limited to patients with increased risk of gastrointestinal complications until results of randomized trials in cardiovascular high-risk populations are published.

Publication Types